C difficile deaths drop after 2011, but seniors, Black Americans, and rural areas still see higher mortality.
A retrospective analysis of nearly 2 decades of US mortality data found that deaths attributed to
The study analyzed 191,653 CDI-attributed deaths recorded in the Centers for Disease Control and Prevention's (CDC) Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database between 1999 and 2020. Investigators calculated age-adjusted mortality rates (AAMR) per 100,000 people to characterize national trends and demographic disparities over the study period.1
The AAMR for CDI-related deaths rose substantially over the first decade of the study period, climbing from 1.1 per 100,000 in 1999 to a peak of 7.3 per 100,000 in 2011—a more than sixfold increase. Following that peak, the AAMR declined to 3.6 per 100,000 by 2020, representing a significant reduction that investigators attributed to improvements in clinical guidelines and management protocols.1 The authors noted that advances in antibiotic stewardship, infection control practices, and treatment availability likely contributed to the downward trend observed across the latter half of the study period.
"Our study has confirmed the decreased mortality related to the disease, which can be attributed to advances in guidelines and management protocols," investigator Mohamed H. Eldesouki, MD, an internal medicine resident at New York Medical College at St. Michael’s Medical Center, and coauthors wrote. "We demonstrated significant differences and variations in CDI mortality with respect to sex, age, race, and geographical location."
Despite the overall decline, older adults continued to account for the largest share of CDI-related deaths throughout the study period. Individuals aged 75 years and older represented 33.11% of all CDI deaths over the full study span; among those older than 85 years, that proportion rose to 37.71%.1 The concentration of mortality in the oldest age groups is consistent with well-established risk factors for severe CDI, including greater comorbidity burden, more frequent healthcare exposure, higher rates of antibiotic use, and diminished immune response.
The majority of CDI deaths occurred in inpatient hospital settings, which accounted for 78.8% of fatalities. Nursing homes accounted for 17% of deaths, and hospice facilities accounted for the remaining 4.6%. The predominance of hospital-based mortality underscores the ongoing importance of healthcare-associated infection prevention measures, whereas the nursing home share reflects the particular vulnerability of long-term care residents—a population characterized by advanced age, frequent antibiotic exposure, and limited physiologic reserve.
The study identified persistent disparities in CDI mortality across racial, ethnic, and geographic groups. Among racial and ethnic categories, non-Hispanic White individuals had the highest overall AAMR at 6.1 per 100,000, followed by non-Hispanic Black individuals at 5.1 and American Indian or Alaska Native individuals at 5.0 per 100,000.1 The authors highlighted non-Hispanic Black individuals and other racial minority groups as populations warranting continued surveillance and targeted public health efforts given the convergence of structural risk factors, including differential healthcare access, higher rates of underlying comorbidities, and documented disparities in infection control resources.
Sarah Parsons, PharmD, BCPPS, FPPA, and Sharon S. Blum, PharmD, BCIDP, write about how systemic antibiotic therapy often leads to significant long-term disruptions to the gut microbiome and how the use of prebiotic fiber, fermented foods, and probiotics is a recommended strategy to minimize microbiome disruption and reestablish a healthy, diverse gut microbial population.
Geographic patterns shifted meaningfully over the study period. Urban areas reported a higher overall AAMR than rural areas across the full period (4.2 vs 3.4 per 100,000), but by 2020, that relationship had reversed, with the rural AAMR (3.2) exceeding the urban figure (2.7). The authors did not ascribe a definitive cause to that reversal, but the pattern is consistent with broader trends in rural health, including reduced access to specialist care, gaps in antibiotic stewardship infrastructure, and lower rates of C difficile-specific diagnostic testing in nonurban settings.
C difficile remains the leading cause of healthcare-associated infectious diarrhea in the United States and was
The authors called for sustained attention to high-risk subgroups despite the overall positive trend. "Continued efforts to improve our understanding of this disease and its trends, particularly in high-risk populations such as the elderly and racial minorities, are essential to further reduce CDI-related mortality in the United States," they concluded.1
